These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 30105359)

  • 1. Real-World Evidence and Real-World Data for Evaluating Drug Safety and Effectiveness.
    Corrigan-Curay J; Sacks L; Woodcock J
    JAMA; 2018 Sep; 320(9):867-868. PubMed ID: 30105359
    [No Abstract]   [Full Text] [Related]  

  • 2. [Not Available].
    Banzi R
    Recenti Prog Med; 2019 Nov; 110(11):526-527. PubMed ID: 31808433
    [No Abstract]   [Full Text] [Related]  

  • 3. Real-world evidence-What is it and does it matter for approval of drugs?
    Eaglstein WH
    J Am Acad Dermatol; 2018 Aug; 79(2):390-391. PubMed ID: 29410344
    [No Abstract]   [Full Text] [Related]  

  • 4. Bill to boost medical research funding and speed drug approval passes US house.
    McCarthy M
    BMJ; 2016 Dec; 355():i6498. PubMed ID: 27908875
    [No Abstract]   [Full Text] [Related]  

  • 5. Real-World Evidence in the Real World: Beyond the FDA.
    Krause JH; Saver RS
    Am J Law Med; 2018 May; 44(2-3):161-179. PubMed ID: 30106647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Boulevard of broken dreams: drug approval for older adults with acute myeloid leukemia.
    Sekeres MA; Steensma DP
    J Clin Oncol; 2012 Nov; 30(33):4061-3. PubMed ID: 23008302
    [No Abstract]   [Full Text] [Related]  

  • 7. Hypothesis: a single clinical trial plus causal evidence of effectiveness is sufficient for drug approval.
    Peck CC; Rubin DB; Sheiner LB
    Clin Pharmacol Ther; 2003 Jun; 73(6):481-90. PubMed ID: 12811358
    [No Abstract]   [Full Text] [Related]  

  • 8. Accelerated approval of oncology drugs: can we do better?
    Ellenberg SS
    J Natl Cancer Inst; 2011 Apr; 103(8):616-7. PubMed ID: 21422401
    [No Abstract]   [Full Text] [Related]  

  • 9. Timing and Characteristics of Cumulative Evidence Available on Novel Therapeutic Agents Receiving Food and Drug Administration Accelerated Approval.
    Naci H; Wouters OJ; Gupta R; Ioannidis JPA
    Milbank Q; 2017 Jun; 95(2):261-290. PubMed ID: 28589600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world studies no substitute for RCTs in establishing efficacy.
    Gerstein HC; McMurray J; Holman RR
    Lancet; 2019 Jan; 393(10168):210-211. PubMed ID: 30663582
    [No Abstract]   [Full Text] [Related]  

  • 11. Feasibility of Using Real-world Data to Emulate Postapproval Confirmatory Clinical Trials of Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval.
    Wallach JD; Zhang AD; Skydel JJ; Bartlett VL; Dhruva SS; Shah ND; Ross JS
    JAMA Netw Open; 2021 Nov; 4(11):e2133667. PubMed ID: 34751763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practice-Based Research Networks and the Mandate for Real-World Evidence.
    Hall-Lipsy E; Barraza L; Robertson C
    Am J Law Med; 2018 May; 44(2-3):219-236. PubMed ID: 30106651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Missing evidence.
    Hayes WS
    MLO Med Lab Obs; 2008 Oct; 40(10):68. PubMed ID: 18988559
    [No Abstract]   [Full Text] [Related]  

  • 14. Accelerated approval of oncology products: the food and drug administration experience.
    Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
    J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Facilitating Both Evidence and Access: Improving FDA's Accelerated Approval and Expanded Access Pathways.
    Lynch HF; Bateman-House A
    J Law Med Ethics; 2020 Jun; 48(2):365-372. PubMed ID: 32631197
    [No Abstract]   [Full Text] [Related]  

  • 16. Has the food and drug administration changed the drug approval process?
    Somberg JC
    Am J Ther; 2011 May; 18(3):179. PubMed ID: 21566467
    [No Abstract]   [Full Text] [Related]  

  • 17. Using real world data to support regulatory approval of drugs in rare diseases: A review of opportunities, limitations & a case example.
    Gross AM
    Curr Probl Cancer; 2021 Aug; 45(4):100769. PubMed ID: 34247834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA under pressure to relax drug rules.
    Ledford H
    Nature; 2012 Dec; 492(7427):19. PubMed ID: 23222585
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluating drug effects in the post-Vioxx world: there must be a better way.
    Avorn J
    Circulation; 2006 May; 113(18):2173-6. PubMed ID: 16684873
    [No Abstract]   [Full Text] [Related]  

  • 20. Moment of reckoning.
    Wadman M
    Nature; 2007 Apr; 446(7138):844-5. PubMed ID: 17443154
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.